- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
- Interventions
- Chemotherapy, Immunotherapy, Laboratory Biomarker Analysis, Lymph Node Biopsy, Ultrasonography
- Drug · Other · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 5
- States / cities
- Conroe, Texas • Houston, Texas • League City, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 139
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
- Procedure · Drug · Biological
- Lead sponsor
- Aseel Alsouqi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Columbus, Ohio • Salt Lake City, Utah
- Conditions
- Prostate Cancer
- Interventions
- flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone
- Diagnostic Test · Drug
- Lead sponsor
- Urology Clinics of North Texas
- Network
- Eligibility
- Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Modified Barium Swallow, Paclitaxel, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography, Technetium Tc 99m-labeled Tilmanocept, Technetium Tc-99m Sulfur Colloid
- Procedure · Drug · Other + 1 more
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Lung Cancer
- Interventions
- chemotherapy, lymphadenectomy, neoadjuvant therapy, quality-of-life assessment, therapeutic conventional surgery, thoracic surgical procedure, fludeoxyglucose F 18, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND, Gemcitabine, Cisplatin
- Biological · Procedure · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
- Biological · Other · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
- Conditions
- Lymphedema, Breast Cancer
- Interventions
- Surgical Intervention, Conservative Complex Physical Decongestion Therapy
- Procedure
- Lead sponsor
- University Hospital, Basel, Switzerland
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Urothelial Carcinoma
- Interventions
- Enfortumab Vedotin, Radical surgery
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- High Grade Upper Tract Urothelial Carcinoma
- Interventions
- Methotrexate, Vinblastine, Doxorubicin, Cisplatin, Gemcitabine, Carboplatin, Pegfilgrastim, Nephroureterectomy
- Drug · Procedure
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 134
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Colorado Springs, Colorado + 93 more
- Conditions
- Prostate Cancer, Localized Prostate Carcinoma
- Interventions
- Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
- Drug · Diagnostic Test · Procedure
- Lead sponsor
- Baptist Health South Florida
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Fluorouracil, Irinotecan, Leucovorin, Lymph Node Biopsy, Magnetic Resonance Imaging, Oxaliplatin, Pembrolizumab, Photodynamic Therapy, Positron Emission Tomography, Questionnaire Administration, Verteporfin
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8
- Interventions
- Cisplatin, Gemcitabine, Nab-paclitaxel
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Rochester, Minnesota • Portland, Oregon + 2 more
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Interventions
- Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Radiosensitizing Agent, Radical Cystectomy, Pelvic Lymphadenectomy, Stereotactic Body Radiation Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Transurethral Resection of Bladder Tumor, Cystoscopy, Biospecimen Collection, Questionnaire Administration
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Shoulder Symptoms After Lymph Node Dissection
- Interventions
- PEMF Device, Sham PEMF Device
- Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
- Interventions
- Trabectedin, Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
- Procedure · Other · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Melanoma (Skin)
- Interventions
- recombinant interferon alfa, lymphangiography, Observation
- Biological · Procedure · Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more
- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil, leucovorin calcium, conventional surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Fluorothymidine F-18, Irinotecan Hydrochloride, Positron Emission Tomography, Therapeutic Conventional Surgery
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, LHRH agonist, surgery
- Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 788 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2030
- U.S. locations
- 221
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
- Conditions
- Pancreas Neoplasm Malignant Resectable
- Interventions
- Folfox6, Gemcitabine, Radiation Therapy, Pancreaticoduodenectomy with retroperitoneal lymphadenectomy
- Drug · Radiation · Procedure
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Breast Cancer, Invasive Breast Cancer
- Interventions
- Pre-neoadjuvant radiotherapy (NART) biopsy, Neoadjuvant radiotherapy, Unilateral total mastectomy with axillary lymph node dissection
- Diagnostic Test · Radiation · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm, Cutaneous Melanoma, Cutaneous Spitz Melanocytoma, Cutaneous Spitz Melanoma
- Interventions
- Biospecimen Collection, Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Re-Excision, Sentinel Lymph Node Biopsy, Ultrasound Imaging, Wide Local Excision
- Procedure · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 13
- States / cities
- Oakland, California • Wilmington, Delaware • Jacksonville, Florida + 10 more